[China Shock, K-Industry on the Brink | Biotech] ③ Chinese Drug Sold for $8.4 Billion: The Results Three Years Later
Tracking Nine Chinese Drug Candidates Licensed Out
Six Candidates Show Results in Phase III Trials
ADC Cancer Drugs Confirmed to Improve Survival
① Big Pharma Sweeps Up Chinese Drug Candidates Wholesale
② Hard to Sell Even Once, but China Sells Them Again and Again
③ Chinese Drug Sold for $8.4 Billion: Results Three Years Later
④ Can South Korea Withstand the Endurance Test of Late-Stage Development?
China's biotech rise is making inroads on the global stage with a steady stream of major achievements. The trend is even more evident in the follow-up research and development (R&D) of drug candidates it has licensed out, according to an analysis. Many major candidates that drew attention across the domestic and global biotech industries have advanced to Phase 3 or later, bringing them close to the final stretch before commercialization.
On October 19, The Asia Business Daily analyzed eight Chinese-originated licensing-out deals from 2023 that were worth at least $1 billion and for which the assets, deal values, and actual transfer of licensing rights could be verified. A total of nine drug candidates were transferred to global Big Pharma companies through these deals. Of these, six reached Phase 3 or achieved meaningful results in Phase 3 within a relatively short period of about two years.
A prominent example is BL-B01D1, an antibody-drug conjugate (ADC) licensed by U.S.-based Bristol Myers Squibb (BMS) from China's SystImmune. The deal was signed in December 2023 for up to $8.4 billion (approximately KRW 11.2392 trillion), with an upfront payment alone of $800 million (approximately KRW 1.0704 trillion). The drug candidate met its primary endpoints in all three Phase 3 trials conducted in China. In June 2026, it significantly improved progression-free survival (PFS) in a Phase 3 trial for triple-negative breast cancer and overall survival (OS) in a separate Phase 3 trial for esophageal cancer.
Other major deals are also advancing into late-stage development. CMG901, a CLDN18.2 ADC licensed by AstraZeneca from KYM Biosciences for up to $1.188 billion (approximately KRW 1.5895 trillion), has advanced from Phase 1 to Phase 3. In July 2026, it was confirmed to have significantly extended overall survival in a Phase 3 trial for gastric and gastroesophageal junction cancers. DB-1303 and DB-1311, ADCs licensed by BioNTech from DualityBio, are also in Phase 3 trials for breast and endometrial cancers, and prostate cancer, respectively.
HS-20093, a B7-H3 ADC licensed by Hansoh Pharmaceutical to GSK, improved overall survival in a Phase 3 trial for small-cell lung cancer in China in July 2026, and its marketing authorization application was accepted in September 2026. HS-20089, a B7-H4 ADC, also entered Phase 3 trials for ovarian and endometrial cancers this year. ECC5004, an oral glucagon-like peptide-1 (GLP-1) candidate licensed by AstraZeneca from China's Eccogene, has completed Phase 2b and is preparing for Phase 3. A trial in patients with obesity this year found weight reductions of up to 11.8% at 36 weeks.
Not only are individual drug candidates advancing, but cases of Chinese drugs undergoing late-stage validation are also increasing. According to the Boston Consulting Group (BCG), there were no Phase 3 head-to-head trials of Chinese-originated drugs against global medicines that still had patent protection in 2020. The number rose to four in 2023, nine in 2024, and six in 2025. Approvals by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for innovative drugs developed in China also increased from two in 2020 to six in 2024. The analysis indicates that Chinese drugs are building a track record of success in late-stage trials and regulatory approvals, rather than stopping at licensing-out deals.
Not all major deals have survived. Ocedurenone, a hypertension treatment acquired by Novo Nordisk from KBP Biosciences in 2023 for up to $1.3 billion (approximately KRW 1.7394 trillion), failed to meet efficacy criteria in an interim analysis of a Phase 3 trial the following year, and development was discontinued. Further development of HRS-1167, a PARP1 inhibitor licensed by Hengrui Pharmaceuticals to Germany's Merck KGaA, also halted after early-stage trials. Of the nine candidates, seven continued into late-stage development, while two fell out of global pharmaceutical companies' development portfolios.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An industry official said, "A licensing deal is only the first evaluation of a drug candidate. What matters is how far the partner has advanced the candidate's development several years after the technology export was announced, rather than the total deal value at the time. Reaching a global Phase 3 trial means that the candidate survived the company's internal development priorities and was judged worthy of continued investment."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.